Physician profile
Benjamin J Schaus
NPI 1891982450
$7,182.62
in general payments reported to CMS, 2019-2025
26 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $151 · 2021: $537 · 2022: $1,399 · 2023: $1,130 · 2024: $1,724 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,674 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,673.60 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,220.02 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,735.54 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $578.56 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $281.24 | 2021-2024 | Zeposia |
| Pfizer INC. | $260.08 | 2019-2025 | |
| Cook Medical LLC | $155.81 | 2019-2022 | |
| Genzyme Corporation | $114.02 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $96.63 | 2023-2025 | Dupixent |
| Braintree Laboratories, INC. | $90.27 | 2019-2024 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $69.36 | 2019-2025 | Rebyota, Cimzia |
| Phathom Pharmaceuticals, INC. | $66.91 | 2023-2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $63.84 | 2020-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.59 | 2021-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $55.47 | 2022-2024 | Dificid |
| Lilly USA, LLC | $53.82 | 2024-2025 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $41.03 | 2022-2023 | Ibsrela |
| Fujifilm Healthcare Americas Corporation | $36.18 | 2023-2024 | Fujifilm |
| Ironwood Pharmaceuticals, INC | $33.40 | 2019-2022 | |
| Daiichi Sankyo INC. | $28.65 | 2022 | |
| Amgen INC. | $25.82 | 2025 | Tavneos |
| Qol Medical, LLC | $24.15 | 2024 | Sucraid |
| Gilead Sciences, INC. | $23.39 | 2024 | |
| Madrigal Pharmaceuticals | $22.84 | 2024 | Resmetirom |
| Ipsen Biopharmaceuticals, INC | $21.57 | 2025 | Iqirvo |
| Allergan, INC. | $11.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Schaus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.